Soleno Therapeutics (SLNO) Cash & Current Investments: 2013-2019
Historic Cash & Current Investments for Soleno Therapeutics (SLNO) over the last 6 years, with Sep 2019 value amounting to $11.2 million.
- Soleno Therapeutics' Cash & Current Investments rose 9.63% to $11.2 million in Q3 2019 from the same period last year, while for Sep 2019 it was $69.2 million, marking a year-over-year increase of 26.33%. This contributed to the annual value of $23.1 million for FY2018, which is 35.08% up from last year.
- Per Soleno Therapeutics' latest filing, its Cash & Current Investments stood at $11.2 million for Q3 2019, which was down 27.59% from $15.5 million recorded in Q2 2019.
- Soleno Therapeutics' Cash & Current Investments' 5-year high stood at $23.1 million during Q4 2018, with a 5-year trough of $2.5 million in Q2 2016.
- In the last 3 years, Soleno Therapeutics' Cash & Current Investments had a median value of $12.6 million in 2018 and averaged $13.4 million.
- In the last 5 years, Soleno Therapeutics' Cash & Current Investments spiked by 7,275.00% in 2015 and then slumped by 66.77% in 2016.
- Quarterly analysis of 5 years shows Soleno Therapeutics' Cash & Current Investments stood at $5.5 million in 2015, then plummeted by 50.39% to $2.7 million in 2016, then surged by 527.29% to $17.1 million in 2017, then skyrocketed by 35.08% to $23.1 million in 2018, then increased by 9.63% to $11.2 million in 2019.
- Its Cash & Current Investments stands at $11.2 million for Q3 2019, versus $15.5 million for Q2 2019 and $19.4 million for Q1 2019.